文献速递皮肤肿瘤

原发性皮肤黑色素瘤前哨淋巴结活检患者组织病理学消退与有利生存相关,转移后免疫检查点抑制剂治疗中无进展生存改善:单机构队列研究

Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study.
PubMed 文献 · J Am Acad Dermatol · 2023-12-01

该单机构回顾性队列纳入2010-2015年新诊断并接受前哨淋巴结活检的皮肤黑色素瘤患者1179例,评估组织病理学消退的预后意义。结果显示消退与有利的无复发生存、无远处转移生存和黑色素瘤特异性生存相关,且与SLN阴性相关;在进展至不可切除阶段的患者中,消退与免疫检查点抑制剂治疗下有利的无进展生存相关,但与靶向治疗或化疗无关。

要点

  • 组织病理学消退与SLN阴性、更好无复发生存、无远处转移生存和黑色素瘤特异性生存相关。
  • 进展至不可切除阶段后,消退与免疫检查点抑制剂治疗下无进展生存改善相关。
  • 消退与靶向治疗或化疗下的无进展生存无关。

核心结论

  • 皮肤黑色素瘤组织病理学消退与适合前哨淋巴结活检患者的改善预后相关。
  • 在不可切除疾病接受免疫检查点抑制剂治疗的患者中,消退也与有利的无进展生存相关。

研究设计与样本

  • 单机构回顾性队列研究,纳入2010-2015年新诊断并接受前哨淋巴结活检、有组织病理学消退信息的黑色素瘤患者1179例。
  • 评估生存数据及临床变量与前哨淋巴结状态的相关性。

临床怎么用

  • 对于接受前哨淋巴结活检的原发性皮肤黑色素瘤患者,组织病理学消退可作为有利预后标志。
  • 对于进展至不可切除阶段并接受免疫检查点抑制剂治疗的患者,消退可能提示更好的无进展生存。

局限性

  • 回顾性、单机构设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Histopathologic regression of cutaneous melanoma is considered a favorable prognostic factor, but its significance in clinical practice remains controversial. OBJECTIVE: To investigate the prognostic importance of regression in patients with primary cutaneous melanoma undergoing sentinel lymph node (SLN) biopsy and to assess its significance in patients progressing to an unresectable stage requiring systemic therapy. METHODS: We retrospectively reviewed patients with newly diagnosed melanoma undergoing SLN biopsy between 2010 and 2015 and available information on histopathologic regression (n = 1179). Survival data and associations of clinical variables with SLN status were assessed. RESULTS: Patients with regressive melanoma showed favorable relapse-free (hazard ratio [HR], 0.52; P = .00013), distant metastasis-free (HR, 0.56; P = .0020), and melanoma-specific survival (HR, 0.35; P = .00053). Regression was associated with negative SLN (odds ratio, 0.48; P = .0077). In patients who progressed to an unresectable stage, regression was associated with favorable progression-free survival under immune checkpoint inhibition (HR, 0.43; P = .031) but not under targeted therapy (HR, 1.14; P = .73) or chemotherapy (HR, 3.65; P = .0095). LIMITATIONS: Retrospective, single-institutional design. CONCLUSIONS: Regression of cutaneous melanoma is associated with improved prognosis in patients eligible for SLN biopsy as well as in patients with unresectable disease receiving systemic therapy with immune checkpoint inhibitors.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wagner NB, Knierim SM, Luttermann F, et al. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study. J Am Acad Dermatol. 2023. PMID: 38043594. doi:10.1016/j.jaad.2023.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。